The clinical paradigm for multiple sclerosis (MS) has witnessed an important shift in recent years, and those dynamics can be attributed to the advent of disease-modifying therapies (DMTs), increased awareness, and the conceptual evolution of MS becoming a treatable disease that requires early and effective intervention to better control the damage process caused by MS. Admittedly, while more patients with MS may be entering the health system through specialist referrals and neurologists, improved diagnostic modalities, such as the advances in neurology and neuro-imaging via MRI scan, arguably still does not explain the increased incidence of MS, and unfortunately, diagnosis of the disease is still not occurring early enough.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More